Udenafil CAS 268203-93-6

Udenafil is the fourth in a class of drugs targeting the inhibition of the enzyme phosphodiesterase 5 (PDE5) for the treatment of erectile dysfunction. Inhibition of PDE5 results in the increase in endogenous cyclic guanosine monophosphate (cGMP) concentrations in the penile corpus cavernosum. cGMP induces smooth muscle cell relaxation and subsequent increased blood flow leading to a sustainable erection. Udenafil is a potent antagonist of human PDE5 with an IC₅₀ of 8.25nM and a comparable selectivity profile as sildenafil for the other PDEs. Unlike tadalafil, it does not inhibit PDE11, which has been implicated in myalgia and testicular toxicity. Furthermore, udenafil produced up to a 91% vaginal penetration success rate and up to a 67% intercourse completion rate compared to a 29% completion rate by placebo. Overall patient satisfaction, measured by a standard global assessment question, was 86% compared to only 26% in the placebo group. The most frequently recorded adverse events were mild-to-moderate facial flushing and headache.

Udenafil is an inhibitor of phosphodiesterase 5 (PDE5). In vivo, udenafil (1 and 5 mg/kg) increases lung cGMP levels, attenuates the development of compensatory right ventricular hypertrophy, and reduces pulmonary arterial wall thickening in a rat model of monocrotaline-induced pulmonary hypertension. It increases creatine clearance and decreases blood urea nitrogen (BUN) and serum malondialdehyde (MDA) levels in a rat model of renal ischemia-reperfusion injury. Udenafil (0.3 and 10 mg/kg) induces penile erections in conscious rabbits and in rabbits with acute spinal cord injury.

Sinemizi-mveliso emininzi ekumgangatho ophezulu enentsebenziswano enzulu, enokubonelela ngeemveliso ezikumgangatho ophezulu kunye namaxabiso akhuphisanayo. Kwaye sinako ukunika izaphulelo zokuthengwa kwezinto ezininzi.Kwaye siyasebenzisana neenkampani ezininzi zokuthunyelwa kwempahla, zinokuzisa iimveliso ngokukhuselekileyo nangokutyibilikayo ezandleni zakho. Ixesha lokuhambisa limalunga neentsuku ezi-3-20 emva kokuqinisekiswa kwentlawulo.

Product Name:	Udenafil
Synonyms:	5-[2-propyloxy-5-(2-(1-Methylpyrrolidin-2-yl)ethylaMinosulphonyl)phenyl]-1-Methyl-3-propyl-6,7-dihydro-1H-pyrazolo(4,3-d)pyriMidin-7-one;5-[2-propyloxy-5-[2-(1-Methyl-2-pyrrolidinyl)ethylaMinosulfonyl]phenyl]-1-Methyl-3-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyriMidine-7-one;Zydena;Udenafil(DA 8159,Zydena);BenzenesulfonaMide,3-(6,7-dihydro-1-Methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyriMidin-5-yl)-N-[2-(1-Methyl-2-pyrrolidinyl)ethyl]-4-propoxy-;Udenafil, DA 8159;CS-1353;Udenafil, >=98%
CAS:	268203-93-6
MF:	C25H36N6O4S
MW:	516.66
EINECS:	251-228-4
Product Categories:	Intermediates & Fine Chemicals;Pharmaceuticals
Mol File:	268203-93-6.mol

1. Ngaba uyifektri okanye inkampani yokurhweba?
Siyinkampani edibanisa ishishini kunye norhwebo, ukubonelela ngenkonzo yokumisa enye.OEM inokwamkelwa.

2. Ngaba ubonelela ngeesampulu? Isimahla okanye yongeziweyo?
Iisampuli zasimahla. Umrhumo womthwalo wesampulu kufuneka uhlawulwe ecaleni kwakho.

3. Ingaba unazo naziphi na izatifikethi ezinxulumene nolawulo lomgangatho?
ISO 9001:2008 isiqinisekiso sokuqinisekisa umgangatho.

4. Ndingenza ntoni ukuze ndifumane ikowuteshini?
I-Pls isazise ngohlobo lwemveliso oyidingayo, ubungakanani beodolo, idilesi kunye neemfuno ezithile. Uqikelelo-mali luya kwenzelwa ireferensi yakho kwangethuba.

5. Loluphi uhlobo lwendlela yokuhlawula oyikhethayo? Ngawaphi amagama amkelweyo?
IMigaqo yoHambiso eyaMkelweyo: FOB,CFR,CIF,EXW;
Imali eyamkelekileyo yeNtlawulo:USD;
Uhlobo lweNtlawulo olwamkelweyo: T/T, Western Union; I-Paypal, iNqinisekiso yoRhwebo.
Ulwimi oluthethwayo:IsiNgesi.